Sigrid Therapeutics Completes Enrollment in SHINE to Evaluate SiPore21® Gel for Sustained Blood Sugar and Weight Management
· SiPore21® offers a non-pharmaceutical oral alternative to injectable drugs for sustainable blood sugar and weight management with no reported loss of lean body mass. · SiPore21® is a gel containing micron-sized mesoporous silica particles (MSPs) that block digestive enzyme-food interactions. · SHINE is the largest ongoing clinical study of its kind, having exceeded its enrollment target with 318 patients with elevated blood sugar levels and excess weight. · SHINE’s primary endpoint is to determine the ability of SiPore21® to reduce patients’ HbA1c levels compared to placebo. ·